Mast Cells as Drivers of Disease and Therapeutic Targets

被引：98
|
作者：
Siebenhaar, Frank [1 ]
Redegeld, Frank A. [2 ]
Bischoff, Stephan C. [3 ]
Gibbs, Bernhard F. [4 ,5 ]
Maurer, Marcus [1 ]
机构：
[1] Charite, Dept Dermatol & Allergy, Berlin, Germany
[2] Univ Utrecht, Div Pharmacol, Dept Pharmaceut Sci, Fac Sci, Utrecht, Netherlands
[3] Univ Hohenheim, Dept Nutr Med & Immunol, Stuttgart, Germany
[4] Univ Kent, Medway Sch Pharm, Canterbury, Kent, England
[5] Carl von Ossietzky Univ Oldenburg, Dept Dermatol & Allergol, Oldenburg, Germany
来源：
TRENDS IN IMMUNOLOGY | 2018年 / 39卷 / 02期
关键词：
RECEPTOR ANTAGONISTS; SYSTEMIC MASTOCYTOSIS; SKIN INFLAMMATION; CATHEPSIN-G; ALLERGEN; DEGRANULATION; INHIBITION; OMALIZUMAB; MEDIATORS; EFFICACY;
D O I：
10.1016/j.it.2017.10.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mast cells (MCs) contribute to the pathogenesis of a multitude of diseases that include MC-driven disorders such as urticaria, type I allergies, and mastocytosis as well as autoimmune and other inflammatory disorders and malignant tumors. Here, we review and discuss the results of studies that identified and characterized how MCs contribute to disease and, importantly, what strategies may be used to target MCs and MC effects therapeutically. Specifically, we discuss the most common approaches for investigating the role and relevance of MCs in various diseases. We also review current therapeutic approaches aimed at modulating MC numbers, inhibiting MCs and/or preventing MC activation, modulating MC signal transduction and protection from the effects of MC mediators.
引用
收藏
页码：151 / 162
页数：12
相关论文
共 50 条
  • [41] CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders
    Santos, Daniel Ditzel
    Hatjiharissi, Evdoxia
    Tournilhac, Olivier
    Chemaly, Mariana Z. A.
    Leleu, Xavier
    Xu, Lian
    Patterson, Christopher
    Branagan, Andrew R.
    Manning, Robert J.
    Ho, Allen W.
    Hunter, Zachary R.
    Dimmock, Elizabeth A.
    Kutok, Jeffery L.
    Churchill, Winthrop H.
    Castells, Mariana C.
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    Treon, Steven P.
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (06) : 478 - 483
  • [42] Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
    Barrera-Chimal, Jonatan
    Jaisser, Frederic
    DIABETES OBESITY & METABOLISM, 2020, 22 : 16 - 31
  • [43] The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease
    Pollock, Carol
    Zuk, Anna
    Anders, Hans-Joachim
    Ganji, Mohammad Reza
    Johnson, David W.
    Kasiske, Bertram
    Langham, Robyn G.
    Pecoits-Filho, Roberto
    Remuzzi, Giuseppe
    Rossert, Jerome
    Suzuki, Yusuke
    Tanaka, Tetsuhiro
    Walker, Robert
    Yang, Chih-Wei
    Bonventre, Joseph V.
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2017, 7 (02) : 130 - 137
  • [44] Podocyte Death in Diabetic Kidney Disease: Potential Molecular Mechanisms and Therapeutic Targets
    Zhong, Suye
    Wang, Na
    Zhang, Chun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [45] Broadening Horizons: Exploring the Cathepsin Family as Therapeutic Targets for Alzheimer's Disease
    Liu, Xiao-Hui
    Liu, Xiao-Tong
    Wu, Yue
    Li, Shu-Ang
    Ren, Kai-Di
    Cheng, Meng
    Huang, Bing
    Yang, Yang
    Liu, Pei-Pei
    AGING AND DISEASE, 2024,
  • [46] HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin
    Olsson, A. G.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2010, 20 (08) : 553 - 557
  • [47] Degranulation of Mast Cells as a Target for Drug Development
    Yang, Bo-Gie
    Kim, A-Ram
    Lee, Dajeong
    An, Seong Beom
    Shim, Yaein Amy
    Jang, Myoung Ho
    CELLS, 2023, 12 (11)
  • [48] Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells
    Mahapatra, Saswati
    Young, Charles Y. F.
    Kohli, Manish
    Karnes, R. Jeffrey
    Klee, Eric W.
    Holmes, Michael W.
    Tindall, Donald J.
    Donkena, Krishna Vanaja
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 2012
  • [49] Bromodomains as therapeutic targets in cancer
    Barbieri, Isaia
    Cannizzaro, Ester
    Dawson, Mark A.
    BRIEFINGS IN FUNCTIONAL GENOMICS, 2013, 12 (03) : 219 - 230
  • [50] Novel therapeutic targets in dermatomyositis
    Bax, Christina
    Aghdasi, Carmel
    Fiorentino, David
    JOURNAL OF DERMATOLOGY, 2024, 51 (07) : 920 - 926
12345